Risk Scores in Secondary Cardiovascular Prevention

20 November 2024

Organised by:

The case

A 62-year-old male patient presents for follow-up six weeks after experiencing an anterior ST-elevation myocardial infarction (STEMI) treated successfully with percutaneous coronary intervention (PCI). He has a history of hyperlipidemia and hypertension. Cardiovascular disease and diabetes mellitus are common in his family, and he is concerned about his long-term prognosis. At night in bed, he experiences bouts of fast, irregular palpitations. Clinical examination is unremarkable and shows regular pulse at 64 beats per minute, and blood pressure 125/75 mmHg. His recent lab results demonstrate normal glycated haemoglobin (HbA1c), well controlled low density lipoprotein (LDL) cholesterol and elevated high sensitivity C-reactive protein (hs-CRP).

References

Question 1: Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model, EJPC, 08 April 2024, https://doi.org/10.1093/eurjpc/zwae096

Question 2: Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions, EJPC, 16 May 2024, https://doi.org/10.1093/eurjpc/zwae174

Question 3: Development and validation of a prognostic score integrating remote heart failure symptoms and clinical variables in mortality risk prediction after myocardial infarction: the PragueMi score, EJPC, 18 March 2024, https://doi.org/10.1093/eurjpc/zwae114

Question 4: Trends in population attributable fraction of modifiable risk factors for cardiovascular diseases across three decades, EJPC, 27 June 2024, https://doi.org/10.1093/eurjpc/zwae219

Question 5: Applying the HARMS2-atrial fibrillation risk score for Japanese population: an analysis of a nationwide epidemiological dataset Get access Arrow, EJPC, 19 March 2024, https://doi.org/10.1093/eurjpc/zwae111